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Method and Process of Consensus Building
The consensus meeting on Consensus meeting on
conjugate vaccines was held on February 17, 2001, as the
first current topic in infectious diseases that was organized
by the Centre of Infection, the University of Hong Kong.
A panel of experts from the fields of Internal Medicine,
Clinical Microbiology, Internal Medicine, Paediatrics and
Public Health were provided with the latest scientific
papers1-8 and were invited to speak and discuss on various
aspects concerning the topic.
After the formal presentation, panel discussion was
held. All speakers, invited discussants from various aspects
of the medical fields and audiences actively participated
in the discussion with further elaboration on issues around
S. pneumoniae and H. influenzae disease burden,
antimicrobial resistance and conjugate vaccine.
Finally, conclusions were drawn on the basis of the
current scientific information and views expressed by the
panel and other participants. Drafts in progress and final
copies of the manuscript were distributed to panel for
comments before submission for publication.
Consensus Panel Members
Daniel CS Chiu, Pediatrician in private practice
Susan SS Chiu, Assistant Professor, Department of
Paediatrics, The University of Hong Kong
CB Chow, Consultant, Department of Paediatrics, Princess
Margaret Hospital
PL Ho, Associate Professor, Department of Microbiology,
The University of Hong Kong
YL Lau, Chair Professor in Paediatrics, Department of
Paediatrics, The University of Hong Kong
CW Leung, Consultant, Department of Paediatrics,
Princess Margaret Hospital
Dominic NC Tsang, Consultant, Department of Clinical
Pathology, Queen Elizabeth Hospital
Kenneth WT Tsang, Associate Professor, Department of
Medicine, University of Hong Kong.
Thomas HF Tsang, Community Physician, Department
of Health
Samson SY Wong, Assistant Professor, Department of
Microbiology, University of Hong Kong.
YH Yang, Professor, Beijing Children's Hospital, Beijing
KY Yuen, Chair Professor in Infectious Diseases,
Department of Microbiology, The University of Hong
Kong
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Invasive Haemophilus Influenzae b Disease:
Overview and Disease Burden in Hong Kong
YL LAU
Chair Professor in Paediatrics, Department of Paediatrics, The University
of Hong Kong
In a position paper on Hib conjugate vaccine, WHO
made the following qualified statement: "In view of the
demonstrated safety and efficacy of the Hib conjugate
vaccines, Hib vaccine should be included, as appropriate
to national capacities and priorities, in routine infant
immunization programmes." This statement highlights the
two major barriers to the implementation of routine infant
Hib immunization in Asia: the cost of Hib vaccine and its
administration which has to be accommodated by "national
capacities"; and the absolute disease burden of Hib diseases
and its relative burden in the broader context of total
disease burden, which will determine the "national
priorities". The disease burden of Hib diseases varies
greatly from one country to another in Asia but on a whole
may be less than that in North America. Better
documentation of burden of disease is not just of academic
interest but indispensable as part of a very complex strategy
to introduce novel but relatively expensive vaccines, such
as Hib and pneumococcal conjugate vaccines. Currently,
the high-income countries in Asia should address this issue
of whether or not to introduce routine Hib immunization
of infants because their "national capacities" could easily
accommodate the cost of the vaccine and its administration;
and even if the incidence of Hib disease in these countries
is low, the benefits of such routine immunization could
be substantial because the indirect medical costs and long-
term treatment costs of Hib morbidity increase with per
capita gross national product (GNP). For example, in Hong
Kong Special Administrative Region of China, where the
estimated incidence of Hib meningitis and bacteremic
pneumonia is only about three per 100,000 children aged
under five years; there would still be about 10 cases per
year, with perhaps one death and two children suffering
sustained permanent neurological sequelae but surviving
for decades, and thus in need of long-term health care.
The net Hib immunization programme cost could be offset
by the savings made in not having to provide care for these
handicapped children for the rest of their lives as well as
the life saved. However, for low-income countries, the
absolute cost involved will be high enough to prohibit
implementation of routine Hib infant immunization,
despite the demonstrated cost-effectiveness of such
programs.
Overview and Disease Burden of Haemophilus
Influenzae Type b in China
YH YANG
Professor, Beijing Children's Hospital, Beijing
Haemophilus influenzae type b (Hib) infections have
been documented in China previously. However, the data
are scanty and incomplete. Hib meningitis accounted for
up to 16% of all pyogenic meningitis during the 1950s. In
the 1900s, it accounted for 30% to 50% of bacterial
meningitis in China. The incidence of Hib meningitis in
Hefei City was 10.4 per 100,000 children <5 years old.9 A
study, supported by the World Health Organization, on
the epidemiologic information of bacterial meningitis in
infants and children with special emphasis on Hib in
Beijing Children's Hospital (BCH) and Hefei City was
completed in 1992. It has studied 128 patients clinically
diagnosed to have bacterial meningitis in BCH from 1988
to 1989. Hib was diagnosed in 37 (29%) of the 128 cases
and 84% was <2 years old. Most of the cases occurred in
winter and spring. The study done in Hefei City from 1990
to 1992, including 13 hospitals in Hefei City, found that
Hib was the most common cause of bacterial meningitis,
accounting for 52% of total cases. The incidence of Hib
meningitis was 10.4 per 100,000 in children <5 years old.
For pneumonia, the yield of culture has been consistently
low due mainly to the prior use of antibiotics. By detection
of antigens, two studies at BCH found evidence of
Hib infection in about one quarter of children with
pneumonia.10 The role of Hib in childhood pneumonia was
further highlighted by the finding of a recent study.11 Of
100 children admitted to the BCH for acute lower
respiratory infections, 8% of them had serological
evidence for Hib etiology. There was no report on other
Hib diseases like epiglottitis, sepsis, pyogenic arthritis and
osteomyelitis available for China. Further surveillance
study in China would be needed in the future.
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Factors to Consider in the Routine Use of Hib in
Hong Kong
Thomas HF TSANG
Community Physician, Department of Health
The routine use of conjugate Hib vaccine is a public
health decision, which should only be made after a careful
assessment of a number of factors, related to the disease
and the vaccine. A major issue concerns the burden of
invasive Hib disease in Hong Kong. Available data
suggested that the disease is much less common locally
than in other industrial countries such as the United States,
Canada, Australia and Finland. Hib is not a notifiable
disease. Notwithstanding this, the department of Health
only received between one to six cases of Hib meningitis
per year. The conjugate Hib vaccine is highly efficacious
(>95%) with relative few and minor side effects (5-30%).
It is accustomed to use one or more of the following
quantitative tools to assess the cost and benefit of a
vaccination program: cost-benefit analysis (CBA), cost-
effectiveness analysis (CEA) and cost-utility analysis
(CUA). Of the CBA performed overseas, the B:C ratio for
routine Hib range between 1.2 to 5.1. In Australia, one
study reported the cost per QALY saved of a routine Hib
program to be between AUS $1231 to 9136. A CBA of
routine Hib program in Hong Kong is difficult to perform
because there is no local consensus on how to calculate
the cost of some parameters such as the long term medical
care, loss in productivity and death. On the basis of an
estimated incidence of five invasive Hib per 100,000
children age ≤5 years, the cost per case of invasive disease
prevented is about 1.6 million. In conclusion, quantitative
assessment of a routine Hib program in Hong Kong is
difficult to perform, due mainly to the lack of certain data.
A consensus economic model on which to base decision
should be developed and validated.
Burden of Pneumococcal Disease in Hong Kong
CB CHOW
Consultant, Department of Paediatrics, Princess Margaret Hospital
Streptococcus pneumoniae causes a spectrum of
diseases. The general breakdown of diseases caused by
pneumococcus is as follows: meningitis (4.1%),
bacteremia without focus (38.7%), bacteremic pneumonia
(53.4%). The incidence of invasive pneumococcal disease
(IPD) is more well defined in the US, the UK and Australia.
In general, the incidence is highest in children ≤2 years of
age, although the absolute incidence varies with countries
and risk factors. The incidence in the US was 165.3/
100,000 population <1 year of age, 203.3/100000 <2 years,
and 37.1-48.1/100,000 and 96.4/100,000 population <1
year in the UK and Australia, respectively. Children with
sickle cell disease and HIV infection also had extremely
high incidence of IPD. Population-based data from Hong
Kong are lacking. The incidence of pneumococcal
septicemia appears low. One study reported that 22% of
septicemia in infants and preschoolers were due to
pneumococcus although the incidence is not known. In
Hong Kong, one study reported an incidence of 5.2/
100,000/year for bacterial meningitis in children <5 years.12
Data from Princess Margaret Hospital between 1976 and
1991 revealed that 76.9% of bacterial meningitis were
culture negative and 5.9% grew S. pneumoniae. Another
study documented 6.4 episodes of community-acquired
pneumonia per 1000 children <5 years of age in Hong
Kong, with pneumococcus accounting for 5%-17%.13
Putting available information together leads to a rough
"guestimate" of the pneumococcal disease burden in Hong
Kong for children <5 years would be: 20/100,000 for
bacteremia, ~1/100,000 for meningitis, 1/1000 for
pneumonia. Better studies to ascertain the disease burden
in Hong Kong is much needed.
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Overview and Disease Burden of Streptococcus
Pneumoniae in China
YH YANG
Professor, Beijing Children's Hospital, Beijing
There were limited data about Streptococcus
pneumoniae infections in China. The first study on the
epidemiology of S. pneumoniae was performed in
collaboration with World Health Organization during
1982-1985. It included 27 hospitals from 18 provinces,
with more than 400 cases of pneumococcal infections. The
rates of pneumococcal pneumonia, meninigitis and otits
media were 14 cases, 79 cases and 68 cases per 1000
homologous disease cases respectively. Most of the cases
were in children less than or equal to three years old. The
mortality rates for pneumococcal pneumonia and
meningitis were 16.4% and 16% respectively. Majority
of them were patients less than 1 year old or more than 50
years old. Overall, the six commonest serotypes found in
this study, in descending order, were 5, 6, 1, 19, 2 and 14.
They accounted for 59% of all S. pneumoniae identified
in the study. In descending order of frequency, the
"pneumonia-related" serotypes were 1, 5, 14, 6, 21 and
28 while the "meningitis-related" serotypes were serotypes
2, 5, 6, 1, 27 and 14. Compared to overseas data, the
incidence of type 5 pneumococcal infections in China was
higher. Another study on acute bacterial meningitis in
children was conducted in Hefei from 1990 to 1992. Of
all the bacterial meningitis in children between the age
of one month to five years old, 8.3% were caused by
S. pneumoniae. The case fatality rate was up to 20%.
Nonetheless, no pneumococcal etiology was detected in a
recent study of 100 children hospitalized for acute lower
respiratory infection.11 Meanwhile, the data is still
incomplete and further studies are now actively undergoing
in China.
Resistance in Pediatric Isolates of Pneumococci.
Results from a Territory-wide Carriage Study
Susan SS CHIU
Assistant Professor, Department of Paediatrics, The University of Hong
Kong
Resistance to penicillin and multiple antibiotics among
Streptococcus pneumoniae  strains is becoming
increasingly problematic worldwide and in Asia.14,15 To
determine the prevalence of carriage of these penicillin-
nonsusceptible Streptococcus pneumoniae isolate in young
children, we obtained nasopharyngeal swab specimens
from 1978 children (ages, two to six years) attending 79
daycare centers or kindergartens. Three hundred and
eighty-three strains of Streptococcus pneumoniae were
isolated from these children. Fifty-eight percent of these
isolates had reduced susceptibility to penicillin; 123
(32.1%) were intermediate and 100 (26.1%) were resistant.
Very high MICs to penicillin (MIC >2 µg/ml) and
cefotaxime (MIC >2 µg/ml) were found in 3.3% and
0.3% of the isolates, respectively. The isolates also
demonstrated high rates of resistance to other antibiotics
(51.2% to cefaclor, 50.2% to cefuroxime, 42.8% to
cefotaxime, 80.7% to trimethoprim-sulfamethoxazole,
77% to erythromycin, 60% to clindamycin and 33.7% to
chloramphenicol). No isolate was resistant to quinolone.
However, 58.7% were resistant to multiple antibiotics, with
extremely high prevalence of 79% in penicillin resistant
isolates. Risk factors for the carriage of penicillin-
nonsusceptible Streptococcus pneumoniae were multiple
physician visits in the preceding three months, and use of
antibiotics by the individual or by household members in
the preceding three months. In the logistic regression
analysis, only the use of antibiotics in the preceding three
months was an independent risk (P=0.004, OR 2, 95% CI
1.2-3.2). This study demonstrated the high prevalence of
antibiotic resistant Streptococcus pneumoniae in healthy
young children in the community in Hong Kong.
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Serotype Distribution of Invasive and Noninvasive
Strains of Pneumococci in Hong Kong
PL HO
Associate Professor, Department of Microbiology, The University of Hong
Kong
The capsular polysaccharide is a major virulence factor
in the pathogenesis of invasive pneumococcal disease. On
the basis of the capsular specificity, the pneumococci can
be grouped into about 90 serogroups and serotypes (SGTs).
While much is known about the SGT distribution of
S. pneumoniae isolates in the Western countries, the
situation in Asian countries is unclear.16 To determine the
coverage of the 7-valent conjugate vaccine for invasive
and noninvasive isolates in Hong Kong, the capsular SGT
of 721 nonduplicate isolates of S. pneumoniae from diverse
sources were determined by the Quellung method.15 Of
the 721 isolates, 383 isolates were obtained from the
nasopharynx (NP) of children age between two to six
years, attending day care centers or kindergartens during
a territory-wide surveillance in 2000, 140 isolates were
obtained from respiratory tract specimens of hospitalized
patients in seven hospitals in 1998, and 199 isolates were
obtained from blood (187) or CSF (12) of patients
hospitalized in four hospitals between 1996 to 2000. SGT
included in the 7-valent pneumococcal conjugate vaccine
were 4, 6B, 9V, 14, 18C, 19F and 23F. At all age groups,
the most common serotypes were 6B, 19F and 23F. Of
the isolates from young children, the 7-valent conjugate
vaccine respectively covered 65%, 88% and 88% of the
NP, respiratory and invasive isolates. Our data showed
that distribution of SGT among invasive and noninvasive
isolates among young children in Hong Kong is similar to
those reported in the United States. On the basis of the
SGT distribution, the recent 7-valent pneumococcal
conjugate vaccine could offer protection against many of
the invasive pneumococcal infections among children in
this locality.
Overview of Conjugate Pneumococcal Vaccine:
Serotype Coverage, Efficacy and Status of Usage
in other Countries
Samson SY WONG
Assistant Professor, Department of Microbiology, The University of Hong
Kong
Streptococcus pneumoniae remains a major cause of
morbidity and mortality even in the developed countries.
It is one of the commonest causes of community-acquired
pneumonia, bacteraemia, meningitis, acute otitis media,
sinusitis, and postsplenectomy sepsis.6 Currently available
vaccines target the polysaccharide capsule, whose
antiphagocytic property is a major virulence factor. Of
the 90 described capsular types, the 23 commonest types
are included in the polysaccharide vaccine, which provides
coverage against 80% to 90% of bacteraemic isolates.7,8
The polysaccharides, however, are poorly immunogenic
in children less than two years of age that are most
susceptible to invasive pneumococcal infections.
Pneumococcal polysaccharides are therefore conjugated
to proteins to improve their immunogenicity in young
children and infants.  A heptavalent conjugate
pneumococcal vaccine was licensed in 2000 in the United
States, which contains serotypes 4, 6B, 9V, 14, 18C, 19F,
and 23F. CRM197, a non-toxic variant of diphtheria toxin,
is used as the protein conjugate. These seven serotypes
accounted for 86% of bacteraemia, 83% of meningitis,
and 65% of acute otitis media in children less than six
years of age in the United States. In a randomized, double-
blinded clinical trial in which ~37,000 children were
recruited, the heptavalent vaccine is ~100% effective in
preventing invasive pneumococcal infections caused by
vaccine serotypes and 89% against all serotypes. There is
a 7.0%-22.8% reduction in the incidence of otitis media
and a 5.3% reduction in antibiotic use in the vaccinees.
The vaccine is presently licensed for use in infants older
than six weeks and is given at two, four, six months, with
a booster dose at 12-15 months. It is recommended for
children less than 23 months old; for children aged 24-59
months, it should be considered for those who are
predisposed to severe pneumococcal disease. A 40%-50%
reduction in nasopharyngeal pneumococcal carriage of
vaccine serotypes is found in field trials of a 9-valent
conjugate vaccine.
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Consensus Statements
Disease burden of paediatric Haemophilus influenzae
type b infections in Hong Kong
1. The incidence of Haemophilus influenzae type b (Hib)
diseases in Hong Kong appears to be low. Multiple
confounding factors, such as prior antibiotic usage,
might be the causes for the apparent low recorded
prevalence.
2. Further study to collect epidemiological data in Hong
Kong would be difficult due to the following factors:
a) Some children might have been given Hib
vaccination on an individual basis.
b) There are quite a number of patients taking
antibiotics prior to collection of specimens
for cultures and the recovery rate of any
microorganisms in these situations is relatively low.
3. Gaps in existing data should be addressed in future
studies using new research methodology, such as the
WHO rapid assessment tool.
Use of conjugate Haemophilus influenzae type b
vaccine
1. Conjugate Hib vaccine has proven safety and efficacy
in prevention of invasive Hib disease.
2. Thorough cost-effective/benefit/utility analysis and
comparison of existing program would be very helpful
in supporting recommendation for universal
vaccination in this locality. Broader discussion/
consultation on what constitute the "acceptable" cost
is required.
Disease burden of pneumococcal infections in Hong
Kong
1. Disease burden of pneumococcal disease is still unclear
and further study would be needed for different at-
risk groups.
2. Penicillin-resistant and multiple antibiotic-resistant
pneumococci are a major problem in Hong Kong.
Use of conjugate pneumococcal vaccine
1. The heptavalent conjugate vaccine provides good
coverage of the serotypes causing invasive
pneumococcal disease in Hong Kong at present.
2. Conjugate pneumococcal vaccine is effective in
decreasing vaccine strain carriage, and preventing
invasive pneumococcal disease in young children from
published experience.
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